CHENODIOL (chenodiol) by Leadiant Biosciences is clinical pharmacology at therapeutic doses, chenodiol suppresses hepatic synthesis of both cholesterol and cholic acid, gradually replacing the latter and its metabolite, deoxycholic acid in an expanded bile acid pool. Approved for cerebrotendinous xanthomatosis (ctx) in adults. First approved in 2009.
Drug data last refreshed 3d ago
CLINICAL PHARMACOLOGY At therapeutic doses, chenodiol suppresses hepatic synthesis of both cholesterol and cholic acid, gradually replacing the latter and its metabolite, deoxycholic acid in an expanded bile acid pool. These actions contribute to biliary cholesterol desaturation and gradual…
Worked on CHENODIOL at Leadiant Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bile Acid